X-Q Liu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

X-Q Liu

Showing results (191-200 of 192) with videos related to

Pageof 20

Sort By:

You have reached the last page of results.This site can display upto 192 results.

Zhonghua Yi Xue Za Zhi|June 14, 2022

[Development of a Ranking Tool for Scientificity, Transparency and Applicability of Clinical Practice Guidelines]N Yang, W Zhao, Y Pan, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized studyY K Shi, L Wang, B H Han, et al.

Pageof 20

Search research articles

Showing results (191-200 of 192) with videos related to

Sort By:

Pageof 20

You have reached the last page of results.This site can display upto 192 results.

Zhonghua Yi Xue Za Zhi|June 14, 2022

[Development of a Ranking Tool for Scientificity, Transparency and Applicability of Clinical Practice Guidelines]N Yang, W Zhao, Y Pan, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized studyY K Shi, L Wang, B H Han, et al.

Pageof 20